File(s) under permanent embargo
Regulatory legitimacy: the case for controlling and restricting access to PGD for sex-selection purposes
Pre-implantation genetic diagnosis embryo screening and assisted reproductive technology Thirty years after the first birth using in vitro fertilisation (IVF), the assisted reproductive technology (ART) debates have continued, raising issues concerning embryo experimentation, including the use of pre-implantation genetic diagnosis (PGD) to screen embryos for genetic characteristics and conditions. PGD is used to screen embryos to assist in deciding which may be judged suitable for implantation. Those not deemed suitable are generally discarded, although they may be used for research purposes, given that any required consent has been obtained. This chapter examines the regulatory regime for PGD in Australia which can be found principally in the National Health and Medical Research Council's (NHMRC) Ethical Guidelines on the Use of Assisted Reproductive Technology and Clinical Practice and Research (2007). Where PGD is used in embryo research, the regulatory regime established by the Research Involving Human Embryos Act 2002 applies. An Australian government committee reviewed this regime, which resulted in revisions to the NHMRC guidelines and to the legislation. This chapter focuses on PGD embryo screening and the regulatory justifications for controlling and restricting access to PGD in ART clinical procedures, with specific reference to its use in sex selection for non-medical reasons.
History
Publication title
Regulating Pre-Implantation Genetic Diagnosis: A comparative and theoretical analysisEditors
Sheila A.M. McLean and Sarah EllistonPagination
148-170ISBN
9780415686440Department/School
Faculty of LawPublisher
RoutledgePlace of publication
OxfordExtent
9Rights statement
Copyright 2013 The AuthorsRepository Status
- Restricted